214 related articles for article (PubMed ID: 29723892)
1. Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).
Coppola A; Franchini M; Castaman G; Santagostino E; Santoro C; Santoro RC; Morfini M; Di Minno G; Rocino A;
Semin Thromb Hemost; 2018 Sep; 44(6):551-560. PubMed ID: 29723892
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
Teitel JM
Transfus Apher Sci; 2018 Aug; 57(4):466-471. PubMed ID: 30093246
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
6. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia.
Franchini M; Marano G; Mengoli C; Piccinini V; Pupella S; Vaglio S; Liumbruno GM
Semin Thromb Hemost; 2018 Sep; 44(6):595-603. PubMed ID: 29165739
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
Zhou ZY; Hay JW
Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
[TBL] [Abstract][Full Text] [Related]
10. New approaches to using FEIBA in the treatment of inhibitor patients.
Berntorp E; Gringeri A; Leissinger C; Négrier C; Key N
Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():22-7. PubMed ID: 16804832
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective.
Messori A
Semin Thromb Hemost; 2018 Sep; 44(6):561-567. PubMed ID: 29220854
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
14. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
Teitel JM; Sholzberg M
Blood Rev; 2013 Mar; 27(2):103-9. PubMed ID: 23452718
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.
Ju HY; Jang HL; Park YS
Blood Res; 2015 Sep; 50(3):173-8. PubMed ID: 26457285
[TBL] [Abstract][Full Text] [Related]
16. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors in Hemophilia: Treatment Challenges and Novel Options.
Barg AA; Livnat T; Kenet G
Semin Thromb Hemost; 2018 Sep; 44(6):544-550. PubMed ID: 29232720
[TBL] [Abstract][Full Text] [Related]
18. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
[TBL] [Abstract][Full Text] [Related]
20. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.
López-Fernández MF; Altisent Roca C; Álvarez-Román MT; Canaro Hirnyk MI; Mingot-Castellano ME; Jiménez-Yuste V; Cid Haro AR; Pérez-Garrido R; Sedano Balbas C
Thromb Haemost; 2016 May; 115(5):872-95. PubMed ID: 26842562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
